April 2015

April 2015

Registration NOW OPEN

for the 2015 Rejuvenation Biotechnology Conference

 

Where: Hyatt Regency San Francisco Airport, Burlingame, CA

When: August 19 - 21, 2015

To Register: http://sens.org/rb2015

SENS Research Foundation is pleased to announce that registration is now open for the 2015 Rejuvenation Biotechnology Conference. For the second year in a row, the Rejuvenation Biotechnology Conference will convene the foremost leaders from academia, industry, investment, policy, and disease advocacy to share knowledge, strategize, and explore the potential for a truly effective approach to managing all age-related disease.
 
Confirmed speakers include:
  • Anthony Atala, Director, Wake Forest Institute for Regenerative Medicine; W.H. Boyce Professor and Chair, Department of Urology at Wake Forest University
  • Chas Bountra, SGC Oxford Chief Scientist, Professor of Translational Medicine, Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology, University of Oxford
  • Judy Campisi, Professor, Buck Institute for Research on Aging
  • Mitch Finer, Chief Science Officer, Bluebird Bio
  • Philip Gregory, Chief Scientific Officer, Sangamo BioSciences Inc.
  • Jeffrey Karp, Associate Professor, Brigham and Women's Hospital, Harvard Medical School
  • Jeanne Loring, Professor, Scripps Research Institute
  • Jan Vijg, Professor, Department of Genetics; Professor, Department of Ophthalmology & Visual Sciences and Chair, Department of Genetics, Albert Einstein School of Medicine
 
We invite everyone in our community to register and participate in our second annual Silicon Valley event. Discounted Super Early Bird ticket rates apply until June 15Book your tickets right away for maximum value. Also make sure to secure your hotel room at the Hyatt Regency San Francisco Airport using this link to receive our special conference rate.
 
Sponsorships are also available
 Click to learn more, or contact:
Jerri Barrett, VP of Outreach
 
Seating is limited so register today!
 
Submit Your Poster Abstract for the RB2015 Poster Session
 
The Rejuvenation Biotechnology Conference Poster Session is now open for abstract submissions. All persons interested in presenting their research are encouraged to go to www.sens.org/rb2015/poster to learn more about the requirements for this year's poster session. Participants will present their work during two evening poster sessions at the conference. Abstracts are due June 1st. Primary authors of accepted abstracts will be notified on July 1, 2015.
 
NEW THIS YEAR: SENS Research Foundation is offering RB2015 Travel Awards to selected student and postdoctoral fellow poster presenters. SRF will reimburse up to $2000 of registration, travel, and hotel costs for each award winner. Prize recipients will present their research during the RB2015 Poster Session. Note that registration includes meals provided during the conference. Travel award winners will be notified by July 15th. To learn more, visit www.sens.org/rb2015/poster.

SRF Education: 2015 Summer Scholars Class Selected

 

SENS Research Foundation is pleased to announce the completion of our evaluation process of an outstanding group of applicants for the 2015 SRF Summer Scholars Program. Sixteen students have been selected to conduct research at eight institutions. Prior host institutions (the Buck Institute for Research on Aging, the Harvard Stem Cell Institute, the University of Oxford, the Wake Forest Institute for Regenerative Medicine and the SRF Research Center) will be joined this year by new host partners Sanford-Burnham Medical Research Institute, the Scripps Research Institute, and Stanford University.
 
 
Starting in June, the SRF Education Blog will begin highlighting the students participating in this year's program. New student profiles will be available every week through August. These blog entries will give you a chance to learn about each student's prior research experiences, current Summer Scholars research project, and future career aspirations.

In the Media

 

Control ALT, Delete Cancer

The Scientist, April 1, 2015

 

This article bears special mention not only due to the subject matter but also due to the authors - SRF Research Center Lead Scientist Haroldo Silva, Research Associate David Halvorsen, and SRF collaborator Jeremy Henson (University of New South Wales). Click the link above to learn how our cancer research team's groundbreaking work is demystifying Alternative Lengthening of Telomeres (ALT), a telomere maintenance mechanism which may be an intervention target for some treatment-resistant cancers.

 

Silicon Valley is Trying to Make Humans Immortal and Having Some Success

Newsweek, March 5, 2015

 

SENS Research Foundation gets a mention in this overview of the emerging phenomenon of aging-mitigation initiatives concentrated in the San Francisco Bay Area. Sensationalistic title aside, Silicon Valley's reputation as a testing ground for bold ideas is well- founded. 

 

The New Age of Much Older Age

Time, February 12, 2015

(Subscriber login required)

 

The next few decades will be crucial to determining how to address age-related disease in a truly effective and comprehensive manner. SRF is not specifically named in this article, but it is worth a look for its emphasis on healthy longevity and its recognition of the priority health should take in moving forward with the scientific approach to aging.

Thank You to our Amazon Smile Users

 

Everyone at SENS Research Foundation would like to thank our supporters who have made us the recipient of their AmazonSmile donations. We just received a check for $972.82 from the AmazonSmile Foundation based on your purchases from October 1 - December 31st. 
 
 
If you'd like to take this opportunity to help fund our fight against age-related disease, it's not too late to join in! Just go to https://smile.amazon.com/ch/94-3473864, sign up, and remember to go to AmazonSmile whenever you are shopping on Amazon.
 

Upcoming Events

 

European Insurance Forum

May 14-15,2015

Croke Park, Dublin, Ireland.

SRF CSO Dr. Aubrey de Grey to speak.

 

Over 40 speakers will present at this event, including some of the world's leading experts in their respective fields. Presenters will discuss the growing global challenges to which insurance providers and policies must determine how to adapt. Aubrey de Grey's talk will explore the ramifications of successful regenerative medicine in the insurance context; Dr. de Grey will also participate in a panel discussing longevity and its impacts on the industry.

Question of the Month #9: What is the role of novel diagnostics in rejuvenation biotechnologies?

 

Q: I'm a biotech graduate currently reading up to produce a PhD proposal. My main areas of interest are in diagnostics, and after reading about rejuvenation biotechnology I've become very interested in contributing to regenerative medicine against ageing. Is there a crossover between diagnostics and the work under SENS Research Foundation? If so I'd love to hear about it.
 
A: There is definitely a need for novel diagnostics, particularly in the course of the critical three decades ahead, as the first rejuvenation biotechnologies enter into human clinical use.
 
As you probably know, rejuvenation biotechnologies are therapies that prevent, arrest, and potentially reverse age-related disease and dysfunction using a "damage-repair"approach. Such therapies work by directly removing, repairing, replacing, or rendering harmless the cellular and molecular damage wrought in our tissues by the biological aging process. This contrasts rejuvenation biotechnology with today's medical approach, in which the target is the metabolic pathways that contribute to such damage instead of the damage itself. Current medicines are thus typically first tested for their effects on the metabolic "risk factors" that ultimately contribute to diseases of aging.
 
Rejuvenation biotechnologies, by contrast, will not directly perturb these metabolic processes (although in some cases they may maintain or restore metabolic processes in youthful condition, when aging normally leads to their dysfunction). Effects on these "risk factors" will therefore either be nonexistent, or manifest themselves many years later, when recipients continue to exhibit youthful metabolic function, in contrast to the age-related aberrations that emerge in untreated aging persons...
 
The "Question of the Month" column is your opportunity to submit your research-related queries to SRF's expert science writer Michael Rae. Please send your questions to foundation@sens.org and they may be featured in a future newsletter.

Want to help spread the word about SRF's mission?

 

Share our vision to Reimagine Aging on

 

   Facebook       @SENSTweet

Please show your support for SRF's work - Donate Today.

 

As a 501(c)(3) public charity, SENS Research Foundation relies on your support

to continue our mission to change the way the world researches and treats age-related disease.

 

 

Visit our donate page to make your contribution.